Vascular Dysfunction in Cardiac Cachexia: Molecular Mechanisms and Pharmacotherapies
Open Access
- 22 December 2025
- journal article
- Published by IMR Press in International Journal of Pharmacology
- Vol. 21 (8)
Abstract
Severe heart failure (HF) is accompanied by cardiac cachexia (CC), defined as significant weight loss, muscle atrophy, and metabolic abnormalities. Muscle wasting in patients with CC is closely associated with hormonal changes. Previous studies on the pathogenesis of CC have focused on the imbalance between catabolic and anabolic processes. Thus, this review focused on the role of endothelial dysfunction in CC. We summarized how inflammatory cytokines and neurohormonal factors cause vascular dysfunction, leading to reduced nutrient delivery and perfusion. Furthermore, we discuss both conventional and emerging therapeutic strategies that may ameliorate CC by targeting the vasculature. These include ghrelin, the vascular benefits of foundational HF drugs (angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and beta-blockers), and the promise of novel agents, such as BTB and CNC homology 1 (BACH1) inhibitors and fibroblast growth factor 21 (FGF21) agonists. We also summarize the existing animal models of CC and discuss advanced imaging and omics technologies for future research. This review provides a novel perspective on CC pathogenesis and highlights promising avenues for therapeutic intervention.Keywords
Funding Information
- National Natural Science Foundation of China (82241030)
This publication has 94 references indexed in Scilit:
- Myocardial Ketone Body Oxidation Contributes to Empagliflozin-Induced Improvements in Cardiac Contractility in Murine Heart FailureEuropean Journal of Heart Failure, 2025
- Cardiac Remodelling in the Era of the Recommended Four Pillars Heart Failure Medical TherapyESC Heart Failure, 2024
- Metabolomics‐driven discovery of therapeutic targets for cancer cachexiaJournal of Cachexia, Sarcopenia and Muscle, 2024
- Inflammation in heart failure: pathophysiology and therapeutic strategiesInflammation Research, 2024
- Biomarkers and mechanisms associated with cancer-induced cardiac cachexia: A systematic reviewJournal of Cachexia, Sarcopenia and Muscle, 2023
- Effects of Empagliflozin on Erythropoiesis in Heart Failure: Data from the Empire HF TrialEuropean Journal of Heart Failure, 2022
- Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db miceJournal of Cachexia, Sarcopenia and Muscle, 2021
- Skeletal Muscle Wasting in Chronic Heart FailureESC Heart Failure, 2018
- Small‐molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexiaJournal of Cachexia, Sarcopenia and Muscle, 2017
- Apoptosis of Skeletal Muscle Myofibers and Interstitial Cells in Experimental Heart FailureJournal of Molecular and Cellular Cardiology, 1998